Vifor Fresenius grants Kissei rights to ANCA-associated AAV candidate avacopan in Japan

Vifor Fresenius Medical Care Renal Pharma Ltd. granted Kissei Pharmaceutical Co. Ltd. (Tokyo:4547) exclusive Japanese rights to develop and commercialize avacopan (CCX168), a candidate to treat antineutrophil cytoplasmic antibody ANCA-associated vasculitis.

Vifor Fresenius Medical Care Renal Pharma Ltd., which is jointly owned by Fresenius SE & Co. KGaA (Xetra:FRE; OTCQX:FSNUY) and Vifor Pharma Ltd. (SIX:VIFN), has rights to the product outside the U.S. and China, where the compound’s originator ChemoCentryx Inc. (NASDAQ:CCXI) retains rights. Vifor declined to disclose financial terms and Kissei did not respond to inquiries...